NeuroPace Announces Upcoming Oral Presentation of Data from the Long-Term Post-Approval Study of the RNS System at the 2025 AAN Annual Meeting

Core Viewpoint - NeuroPace, Inc. is focused on addressing the unmet medical needs of patients with drug-resistant focal epilepsy (DRE) through its innovative RNS® System, which will be presented at the AAN 2025 Annual Meeting [1][2]. Company Overview - NeuroPace is a commercial-stage medical device company based in Mountain View, California, dedicated to transforming the lives of people with epilepsy by reducing or eliminating debilitating seizures [5]. - The RNS System is the first and only commercially available brain-responsive platform that provides personalized, real-time treatment at the seizure source, aiming to improve care standards for patients with DRE [5]. Upcoming Events - NeuroPace will present data from the Post-Approval Study (PAS) of the RNS System at the AAN 2025 Annual Meeting in San Diego from April 5 to 9, with a specific oral presentation scheduled for April 7 [1][7]. - The RNS System will be showcased at booth 1642 during the event [2][4]. Leadership Insights - Joel Becker, CEO of NeuroPace, emphasized the significant unmet medical need for patients with DRE and expressed the company's commitment to improving outcomes for this population [2].